Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model

Cancer Immunology, Immunotherapy

Volumn 65, Issue 12, 2016, Pages 1491-1498

  Dyck, Lydia ^a   Wilk, Mieszko M ^a   Raverdeau, Mathilde ^a   Misiak, Alicja ^a   Boon, Louis ^b   Mills, Kingston H G ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b BIOCEROS   (Netherlands)

Author keywords

Co inhibitory molecule; Murine tumour model; PD 1; T cell; Treg cell; Vaccine

Indexed keywords

ANTIBODY; CANCER VACCINE; GAMMA INTERFERON; PROGRAMMED DEATH 1 RECEPTOR; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY ASSAY; EFFECTOR CELL; FLOW CYTOMETRY; IMMUNITY; LEUKOCYTE; LYMPH NODE; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; SURVIVAL; T LYMPHOCYTE; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; IMMUNOLOGY; METABOLISM;

ANIMALS; CANCER VACCINES; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, REGULATORY;

EID: 84988943934     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1906-6     Document Type: Article

References (22)

1. Tjin EP, Krebbers G, Meijlink KJ et al (2014) Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy. Cancer Immunol Res 2:538–546
2. Dudley ME, Yang JC, Sherry R et al (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26:5233–5239
3. Butt AQ, Mills KH (2014) Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene 33:4623–4631
4. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295–307
5. Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949
6. van der Burg SH, Arens R, Ossendorp F, van Hall T, Melief CJ (2016) Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 16:219–233
7. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM (2003) Conversion of peripheral CD4+ CD25- naive T cells to CD4+ CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198:1875–1886
8. Galvin KC, Dyck L, Marshall NA, Stefanska AM, Walsh KP, Moran B, Higgins SC, Dungan LS, Mills KH (2013) Blocking retinoic acid receptor-alpha enhances the efficacy of a dendritic cell vaccine against tumours by suppressing the induction of regulatory T cells. Cancer Immunol Immunother 62:1273–1282
9. Conroy H, Galvin KC, Higgins SC, Mills KH (2012) Gene silencing of TGF-beta1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells. Cancer Immunol Immunother 61:425–431
10. Jarnicki AG, Lysaght J, Todryk S, Mills KH (2006) Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 177:896–904
11. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264
12. Wherry EJ, Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15:486–499
13. Freeman GJ, Long AJ, Iwai Y et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192:1027–1034
14. Latchman Y, Wood CR, Chernova T et al (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2:261–268
15. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T (2013) A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14:1212–1218
16. Kataoka K, Shiraishi Y, Takeda Y et al (2016) Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers. Nature 534:402–406
17. Callahan MK, Postow MA, Wolchok JD (2016) Targeting T Cell Co-receptors for cancer therapy. Immunity 44:1069–1078
18. Sidaway P (2016) Bladder cancer: Atezolizumab effective against advanced-stage disease. Nat Rev Urol 13:238
19. Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34
20. Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, Noelle RJ (2008) Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+ CD4+ regulatory T cells. Proc Natl Acad Sci USA 105:9331–9336
21. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206:3015–3029
22. Wei J, Duramad O, Perng OA, Reiner SL, Liu YJ, Qin FX (2007) Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 104:18169–18174